<SEC-DOCUMENT>0001157523-15-002492.txt : 20150724
<SEC-HEADER>0001157523-15-002492.hdr.sgml : 20150724
<ACCEPTANCE-DATETIME>20150724060147
ACCESSION NUMBER:		0001157523-15-002492
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20150724
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150724
DATE AS OF CHANGE:		20150724

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AGENUS INC
		CENTRAL INDEX KEY:			0001098972
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				061562417
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29089
		FILM NUMBER:		151003356

	BUSINESS ADDRESS:	
		STREET 1:		3 FORBES ROAD
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421
		BUSINESS PHONE:		781-674-4410

	MAIL ADDRESS:	
		STREET 1:		3 FORBES ROAD
		CITY:			LEXINGTON
		STATE:			MA
		ZIP:			02421

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANTIGENICS INC /DE/
		DATE OF NAME CHANGE:	19991115
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a51148680.htm
<DESCRIPTION>AGENUS INC. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2015 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 10pt; font-family: Times New Roman">
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 12pt"><b>UNITED
      STATES</b></font><b><font style="font-family: Times New Roman; font-size: 12pt"><br style="font-size: 12pt; font-family: Times New Roman"></font><font style="font-family: Times New Roman; font-size: 12pt">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-family: Times New Roman; font-size: 10pt"><b>Washington,
      D.C. 20549</b></font><br>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 18pt"><b>FORM 8-K</b></font>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 12pt"><b>CURRENT
      REPORT</b></font><br><font style="font-family: Times New Roman; font-size: 12pt"><b>Pursuant
      to Section 13 or 15(d) of</b></font><br><font style="font-family: Times New Roman; font-size: 12pt"><b>
      the Securities Exchange Act of 1934</b></font><br><font style="font-family: Times New Roman; font-size: 10pt">July
      24, 2015</font><br><font style="font-family: Times New Roman; font-size: 10pt">Date
      of Report (Date of earliest event reported)</font><br><br>
    </p>
    <hr style="height: 1.0 pt; text-align: center; color: #000000; width: 100%">


    <p style="text-align: center">
      <font style="font-size: 14pt"><b>AGENUS INC.</b></font><br><font style="font-family: Times New Roman; font-size: 10pt">(Exact
      name of registrant as specified in its charter)</font><br><br><br>
    </p>
    <hr style="height: 1.0 pt; text-align: center; color: #000000; width: 100%">

<div style="text-align:left">

    <table style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 10pt" cellspacing="0">
      <tr>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; width: 33%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>DELAWARE</b>
          </p>
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; white-space: nowrap; width: 34%; padding-right: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>000-29089</b>
          </p>
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; white-space: nowrap; width: 33%; padding-right: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>06-1562417</b>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; width: 33%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (State or other jurisdiction
          </p>
          <p style="margin-top: 0px; margin-bottom: 0px">
            of incorporation)
          </p>
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; width: 34%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (Commission
          </p>
          <p style="margin-top: 0px; margin-bottom: 0px">
            File Number)
          </p>
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; width: 33%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (IRS Employer
          </p>
          <p style="margin-top: 0px; margin-bottom: 0px">
            Identification No.)
          </p>
        </td>
      </tr>
    </table>
    </div>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 10pt" cellspacing="0">
      <tr>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; width: 50%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>3 Forbes Road</b>
          </p>
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Lexington, MA</b>
          </p>
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; white-space: nowrap; width: 50%; padding-right: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>02421</b>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; width: 50%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <font style="font-family: Times New Roman; font-size: 10pt">(Address
            of principal executive offices)</font>
          </p>
        </td>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px; width: 50%">
          <font style="font-family: Times New Roman; font-size: 10pt">(Zip
          Code)</font>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt"><b>781-674-4400</b></font><font style="font-family: Times New Roman; font-size: 10pt"><br style="font-family: Times New Roman; font-size: 10pt"></font><font style="font-family: Times New Roman; font-size: 10pt">(Registrant&#8217;s
      telephone number, including area code)</font>
    </p>
    <p>

    </p>
    <hr style="text-align: center; height: 1.0 pt; color: #000000; width: 100%">


    <p>
      <br>
      Check the appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions (see General Instruction A.2. below):<br><font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font><br><font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font><br><font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font><br><font style="font-family: Arial Unicode MS; font-size: 10pt">&#8414;</font>
      <font style="font-family: Times New Roman; font-size: 10pt">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font><br>
    </p>
    <div style="margin-right: 0pt; text-indent: 0pt; margin-bottom: 10pt; width: 100%; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">

    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 10pt" cellspacing="0">
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 8%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Item 8.01</b>
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 2%">
          &#160;
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 90%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Other events</b>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>
      Agenus Inc. today announced that GlaxoSmithKline received a positive
      opinion for its Malaria vaccine candidate from the Committee for
      Medicinal Products for Human Use of the European Medicines Agency. The
      vaccine candidate, named Mosquirix&#8482; (RTS,S) is the first QS-21 Stimulon
      containing product to receive a positive regulatory decision. Agenus&#8217;
      adjuvant QS-21 is designed to increase immune response to antigens in
      vaccines. The positive opinion signals that Mosquirix meets the
      necessary quality, safety and efficacy requirements according to EU
      standards.
    </p>
    <p>
      The full text of the press release issued in connection with the
      announcement is attached hereto as Exhibit 99.1and is incorporated
      herein by reference.
    </p>
    <p>
      <br>

    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 10pt" cellspacing="0">
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 8%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Item 9.01</b>
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 2%">
          &#160;
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 90%">
          Financial Statements and Exhibits
        </td>
      </tr>
    </table>
    </div>
    <p style="text-indent: 30.0px; font-size: 10pt">
      (d) Exhibits
    </p>
    <p style="text-indent: 30.0px; font-size: 10pt">
      The following exhibit is filed herewith:
    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 10pt" cellspacing="0">
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 10%">
          &#160;
        </td>
        <td valign="bottom" style="text-align: left; padding-left: 0.0px; width: 90%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            99.1 &#160;&#160;&#160;&#160;Press Release dated July 24, 2015
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-indent: 60.0px; font-size: 10pt">

    </p>
    <div style="margin-right: 0pt; text-indent: 0pt; margin-bottom: 10pt; width: 100%; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt"><b>SIGNATURES</b></font>
    </p>
    <p>
      <font style="font-family: Times New Roman; font-size: 10pt">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the Registrant
      has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</font>
    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 10pt" cellspacing="0">
      <tr>
        <td style="width: 75%">

        </td>
        <td valign="top" colspan="2" style="text-align: right; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>AGENUS INC.</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 75%">

        </td>
        <td valign="top" colspan="2" style="text-align: left; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px; width: 75%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date: July 24, 2015
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px; width: 5%">
          By:
        </td>
        <td valign="top" style="text-align: right; border-bottom: solid black 1.0pt; padding-left: 0.0px; width: 20%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            /s/ Garo H. Armen
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 75%">

        </td>
        <td valign="top" colspan="2" style="text-align: left; padding-left: 0.0px">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 75%">

        </td>
        <td valign="top" colspan="2" style="text-align: right; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Garo H. Armen
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 75%">

        </td>
        <td valign="top" colspan="2" style="text-align: right; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Chief Executive Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
    <div style="margin-right: 0pt; text-indent: 0pt; margin-bottom: 10pt; width: 100%; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: left">
      EXHIBIT INDEX<br><br>
    </p>
<div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 10pt" cellspacing="0">
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 12%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <u>Exhibit No.</u>
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 5%">
          &#160;
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 83%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <u>Description of Exhibit</u>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 12%">

        </td>
        <td style="width: 5%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 83%">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px; white-space: nowrap; width: 12%; padding-right: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            99.1
          </p>
        </td>
        <td style="width: 5%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 83%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Press Release dated July 24, 2015
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51148680ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2015 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 8pt; font-family: Times New Roman">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 12pt"><b>GSK&#8217;s
      Malaria Vaccine Containing Agenus&#8217; QS-21 Stimulon</b></font><b><sup><font style="font-family: Times New Roman; font-size: 12pt">&#174;</font></sup><font style="font-family: Times New Roman; font-size: 12pt">
      Receives Positive Opinion from European Regulators for Prevention of
      Malaria in Young Children in Sub-Saharan Africa</font></b>
    </p>
    <p>
      LEXINGTON, Mass.--(BUSINESS WIRE)--July 24, 2015--Agenus Inc.
      (NASDAQ:AGEN), an immunology company discovering and developing
      innovative treatments for cancers and other diseases, today announced
      that GlaxoSmithKline (NYSE: GSK) received a positive opinion for its
      Malaria vaccine candidate from the Committee for Medicinal Products for
      Human Use (CHMP) of the European Medicines Agency (EMA). The vaccine
      candidate, named Mosquirix&#8482; (RTS,S) is the first QS-21 Stimulon
      containing product to receive a positive regulatory decision. Agenus&#8217;
      adjuvant QS-21 is designed to increase immune response to antigens in
      vaccines. The positive opinion signals that Mosquirix meets the
      necessary quality, safety and efficacy requirements according to EU
      standards.
    </p>
    <p>
      &#8220;This is a significant&#160;milestone for the field of Malaria and our QS-21
      Stimulon, which is an integral component of the adjuvant contained in
      Mosquirix, the first malaria candidate vaccine to generate positive
      Phase 3 data, now awaiting the World Health Organization&#8217;s
      recommendations and approvals by African Health authorities,&#8221; commented
      Garo Armen, Ph.D., Chairman and CEO of Agenus. &#8220;We look forward to
      seeing Mosquirix achieve the required final clearances so it can begin
      benefiting children at risk of contracting and dying from Malaria.&#8221;
    </p>
    <p>
      The CHMP scientific opinion is a key step in the regulatory process
      toward making a vaccine against Malaria available. The positive opinion
      follows review by the CHMP of the candidate vaccine&#8217;s safety, efficacy
      and quality. Clinical data supporting the filing were mainly from a
      Phase 3 clinical program involving more than 16,000 infants and young
      children.
    </p>
    <p>
      Following the CHMP positive opinion, two of the World Health
      Organization&#8217;s (WHO) independent advisory groups, the Strategic Advisory
      Group of Experts (SAGE) on Immunization and the Malaria Policy Advisory
      Committee (MPAC), will now jointly review the evidence base for the
      vaccine candidate and make a joint policy recommendation for how the
      vaccine should be used in the event that it ultimately is approved by
      the national regulatory authorities in the sub-Saharan African countries
      for which the vaccine is intended. The WHO has indicated that such a
      policy recommendation may be possible by end of this year.
    </p>
    <p>
      <b>About QS-21 Stimulon&#174;</b>
    </p>
    <p>
      QS-21 Stimulon is a saponin extracted from the bark of the <i>Quillaja
      saponaria</i> tree, an evergreen also known as the soap bark tree. The
      adjuvant is a key component of investigational vaccines to prevent a
      wide variety of infectious diseases, and therapeutic vaccines for cancer
      and degenerative disorders. QS-21 Stimulon has been evaluated in
      approximately 50,000 individuals and patients. Agenus is entitled to
      receive a modest milestone payment upon approval of the first licensed
      product with GSK, as well as low single digit royalties on potential
      commercial sales for 10 years after commercial launch, with some
      exceptions.
    </p>
    <div style="margin-right: 0pt; text-indent: 0pt; margin-bottom: 10pt; width: 100%; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="height: 1.5pt; color: black">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>About Agenus</b>
    </p>
    <p>
      Agenus is an immunology company engaged in the discovery and development
      of novel checkpoint modulators, vaccines and adjuvants to treat cancer
      and other diseases. Using its proprietary platforms Retrocyte Display&#8482;
      and SECANT&#174;, the Company is discovering and developing novel antibodies
      to target GITR, OX40, CTLA-4, LAG-3, TIM-3, PD-1 and other undisclosed
      checkpoints in partnered and internal programs. Agenus&#8217; heat shock
      protein vaccine, Prophage, has successfully completed Phase 2 studies in
      newly diagnosed glioblastoma multiforme. The Company&#8217;s QS-21 Stimulon&#174;
      adjuvant is extensively partnered with GlaxoSmithKline and Janssen
      Sciences Ireland UC, and two vaccine candidates containing QS-21 have
      successfully completed Phase 3 trials. For more information, please
      visit <u>www.agenusbio.com</u>, or follow the company on Twitter
      @Agenus_Bio; information that may be important to investors will be
      routinely posted in these locations.
    </p>
    <p>
      <b>Forward-Looking Statements</b>
    </p>
    <p>
      <i>This press release contains forward-looking statements that are made
      pursuant to the safe harbor provisions of the federal securities laws,
      including statements regarding the expected benefit from GSK&#8217;s
      Mosquirix&#8482; vaccine, the potential milestone and royalties payable to
      Agenus and the Company&#8217;s potential to create best-in-class combination
      therapies for treating patients with cancer. These forward-looking
      statements are subject to risks and uncertainties that could cause
      actual results to differ materially. These risks and uncertainties
      include, among others, the factors described under the Risk Factors
      section of Agenus&#8217; Prospectus Supplement filed with the Securities and
      Exchange Commission on May 21, 2015. Agenus cautions investors not to
      place considerable reliance on the forward-looking statements contained
      in this release. These statements speak only as of the date of this
      press release, and Agenus undertakes no obligation to update or revise
      the statements, other than to the extent required by law. All
      forward-looking statements are expressly qualified in their entirety by
      this cautionary statement.</i>
    </p>
    <p>

    </p>
    <p>
      CONTACT:<br><b>Media:</b><br>BMC Communications<br>Brad Miles,
      646-513-3125<br><u>bmiles@bmccommunications.com</u><br>or<br><b>Investors:</b><br>Argot
      Partners<br>Andrea Rabney, 212-600-1902<br><u>andrea@argotpartners.com</u><br>or<br>Jamie
      Maarten, 212-600-1902<br><u>jamie@argotpartners.com</u>
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
